CTI Biopharma Corp expected to post a loss of 28  cents a share - Earnings Preview

CTI Biopharma

12/03/2022 24:23

* CTI Biopharma Corp  CTIC.OQ   CTIC.O  is expected to show
no
change in quarterly revenue when it reports  results on March 15
(estimated). 
    * ​Refinitiv's mean analyst estimate for CTI Biopharma Corp
is for
a loss of 28 cents per share. For the same quarter last year,
the company reported a loss of 20 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CTI
Biopharma
Corp is $8.5​, above​ its last closing price of $4.59. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.22       -0.25      -0.26     Missed  -4.7
 Jun. 30 2021  -0.21       -0.21      -0.21     Met     0
 Mar. 31 2021  -0.22       -0.22      -0.23     Missed  -5.7​
 Dec. 31 2020              -0.16      -0.20     Missed  -27
 ​​Sep.        -0.15       -0.15      -0.15     Met     2.2
 30 2020                                                
 Jun. 30 2020  -0.12       -0.12      -0.14     Missed  -13.5​
 Mar. 31 2020  -0.13       -0.13      -0.20     Missed  -53.8
 Dec. 31 2019  -0.21       -0.22      -0.14     Beat    37.8
 This summary was machine generated March 12 at 00:23 GMT.  All
figures in US dollars  unless otherwise stated